SEC Filings

Form 8-K
BEIGENE, LTD. filed this Form 8-K on 08/10/2017
Document Outline
Entire Document (3575 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - UNITED STATES
Page 2 - Item 2.02
Page 3 - Forward Looking Statements
Page 4 - SIGNATURES
Page 5 - Exhibit Index
Subdocument 2 - EX-99.1 - EX-99.1
Page 1 - Exhibit 99.1
Page 2 - BGB-A317
Page 3 - BGB-290
Page 4 - Corporate Development:
Page 5 - BGB-A317 (PD-1 Antibody)
Page 6 - Revenue
Page 7 - Financial Summary
Page 8 - Consolidated Statements of Comprehensive Loss (U.S. GAAP)
Page 9 - Investor/Media Contact
Subdocument 3 - EX-99.2 - EX-99.2
Page 1 - Exhibit 99.2
Page 2 - About BeiGene
Page 3 - Investor/Media Contact
Subdocument 4 - EX-99.3 - EX-99.3
Page 1 - Exhibit 99.3
Page 2 - N/A
Page 3 - Recent Developments
Page 4 - antitrust laws and satisfaction of other customary closing conditions. The principal agreements for
Subdocument 5 - EX-99.4 - EX-99.4
Page 1 - Exhibit 99.4
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - 34 Near-term Milestones and Plans Event Expected Timing BGB-3111 (BTK Inhibitor) Present data from t